Andrade Mena C E, Orbach-Arbouys S, Mathé G
Chemotherapy. 1986;32(2):142-7. doi: 10.1159/000238406.
Aclacinomycin (ACM) a new cytotoxic antibiotic employed in cancer chemotherapy, can either enhance or inhibit the NK-cell activity of the immune system, depending on the dose administered. A single intraperitoneal injection of 2-4 mg/kg of ACM augments the cytolytic activity by spleen and peritoneal exudate cells of normal mice and spleen cells depleted of nylon-adherent cells and peritoneal exudate cells of tumor-bearing mice. In contrast to the stimulatory effect of NK-cell activity by low doses of ACM, a single injection of 8 mg/kg of this agent leads to depression in the level of NK-cell activity in both normal and tumor-bearing animals. We suggest that the mechanism through which the ACM enhances NK-cell activity may be through the deletion of a suppressor cell population acting on the NK cells.
阿克拉霉素（ACM）是一种用于癌症化疗的新型细胞毒性抗生素，根据给药剂量的不同，它可以增强或抑制免疫系统的自然杀伤细胞（NK细胞）活性。单次腹腔注射2 - 4毫克/千克的阿克拉霉素可增强正常小鼠脾脏和腹腔渗出细胞以及荷瘤小鼠去除尼龙黏附细胞后的脾脏细胞和腹腔渗出细胞的溶细胞活性。与低剂量阿克拉霉素对NK细胞活性的刺激作用相反，单次注射8毫克/千克该药物会导致正常动物和荷瘤动物的NK细胞活性水平降低。我们认为，阿克拉霉素增强NK细胞活性的机制可能是通过去除作用于NK细胞的抑制性细胞群体来实现的。
